Inflammation-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis has been suggested to depend on prostaglandins, but the prostaglandin species and the prostaglandin-synthesizing enzymes that are responsible have not been fully identified. Here, we examined HPA axis activation in mice after genetic deletion or pharmacological inhibition of prostaglandin E 2 -synthesizing enzymes, including cyclooxygenase-1 (Cox-1), Cox-2, and microsomal prostaglandin E synthase-1 (mPGES-1). After immune challenge by intraperitoneal injection of lipopolysaccharide, the rapid stress hormone responses were intact after Cox-2 inhibition and unaffected by mPGES-1 deletion, whereas unselective Cox inhibition blunted these responses, implying the involvement of Cox-1. However, mPGES-1-deficient mice showed attenuated transcriptional activation of corticotropin-releasing hormone (CRH) that was followed by attenuated plasma concentrations of adrenocorticotropic hormone and corticosterone. Cox-2 inhibition similarly blunted the delayed corticosterone response and further attenuated corticosterone release in mPGES-1 knock-out mice. The expression of the c-fos gene, an index of synaptic activation, was maintained in the paraventricular hypothalamic nucleus and its brainstem afferents both after unselective and Cox-2 selective inhibition as well as in Cox-1, Cox-2, and mPGES-1 knock-out mice. These findings point to a mechanism by which (1) neuronal afferent signaling via brainstem autonomic relay nuclei and downstream Cox-1-dependent prostaglandin release and (2) humoral, CRH transcription-dependent signaling through induced Cox-2 and mPGES-1 elicited PGE 2 synthesis, shown to occur in brain vascular cells, play distinct, but temporally supplementary roles for the stress hormone response to inflammation.
Introduction
Immune-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis with increased release of adrenocorticotropic hormone (ACTH) and corticosteroids is critical for the finetuning of the inflammatory response (Besedovsky et al., 1986) . It has been suggested that this activation is regulated by prostaglandins because it is attenuated after administration of cyclooxygenase (Cox) inhibitors (Krymskaya et al., 1987; Katsuura et al., 1988; Morimoto et al., 1991; Dunn and Chuluyan, 1992; Watanobe et al., 1998) , although conflicting data also exist (Turnbull and Rivier, 1999) .
Several lines of evidence indicate that prostaglandin E 2 (PGE 2 ) is the prostanoid involved. These include findings that injection of PGE 2 into the brain elicits ACTH release (Katsuura et al., 1990; Watanabe et al., 1990; McCoy et al., 1994) and that mice with targeted deletions of PGE 2 receptor subtypes EP 1 and EP 3 display impaired ACTH response to bacterial endotoxin (Matsuoka et al., 2003) . However, PGE 2 is produced both under constitutive conditions and in response to homeostatic challenges, and the role of different PGE 2 -synthesizing pathways in the immuneelicited activation of the HPA axis as well as the signaling routes remain to be clarified. Constitutive PGE 2 production occurs preferentially via Cox-1, whereas the induced PGE 2 formation is mediated by Cox-2. In both cases, an intermediate, PGH 2 , is synthesized, which is the substrate for the prostanoid-specific terminal enzymes. For PGE 2 , several terminal enzymes have been identified, among them the inducible microsomal prostaglandin E synthase-1 (mPGES-1), shown to be critical for the febrile response during inflammation Saha et al., 2005) and for cytokine-elicited anorexia (Pecchi et al., 2006; Elander et al., 2007) .
In the present study, we addressed the role of different PGE 2 -synthesizing pathways for the HPA axis activation in mice with deletion of the gene encoding Cox-1, Cox-2, and mPGES-1, respectively, as well as in mice treated with unselective or Cox-2 selective inhibitors. The mice were injected intraperitoneally with lipopolysaccharide (LPS), and plasma levels of ACTH and corticosterone were monitored. Furthermore, to elucidate which structures involved in the activation of the stress hormone response were sensitive to induced PGE 2 synthesis, corticotropinreleasing hormone (CRH) gene expression in the hypothalamus was examined, as was the expression of the immediate-early gene c-fos [an index of synaptic activation (Hunt et al., 1987; Luckman et al., 1994) ] in the paraventricular hypothalamic nucleus (PVH) and upstream brainstem regions, including catecholamineexpressing medullary neurons (Ericsson et al., 1994) . The results show that the sustained immune-induced ACTH and corticosterone release occurs in response to induced PGE 2 synthesis, known to take place in brain vascular cells ) and that it is associated with blunted CRH gene transcription. In contrast, the rapid response is independent of induced PGE 2 synthesis by Cox-2 and mPGES-1, and probably elicited by Cox-1. The findings imply that constitutive and induced prostaglandinsynthesizing enzymes act in a temporally supplementary sequence, involving neural and humoral routes, respectively, in creating the HPA axis response to inflammation.
Materials and Methods
Animals and tissue collection. All experimental procedures were approved by the Animal Care and Use Committee at Linköping University. They were performed on adult mice of the following strains: Ptgs1 Ϫ/Ϫ [Cox-1 knock-out (KO)] and Ptgs2 Ϫ/Ϫ (Cox-2 knock-out) and their respective wild-type littermates on a mixed B6;129P2 background (Morham et al., 1995; Langenbach et al., 1997) , obtained by our own heterozygous breeding (breeding pairs were a gift from Robert Langenbach, National Institute of Environmental Health Sciences, Research Triangle Park, NC); Ptgs2 Ϫ/Ϫ mice on a mixed B6;129P2 background (Morham et al., 1995) , with separately bred wild-type mice of the same background used as controls (from Taconic); Ptges Ϫ/Ϫ (mPGES-1 knock-out) mice on a DBA/lacJ background (Trebino et al., 2003) , which were generated both by homozygous breeding, in which case wild-type controls on the same background were used, and by heterozygous breeding on a line that had been backcrossed for six generations with DBA/lacJ wild-type mice, with wild-type littermates serving as controls; and wild-type C57/B6 mice (Scanbur). The animals were housed one to a cage in a pathogen-free facility at 20°C with a regular 12 h light/dark cycle (lights on, 7:00 A.M.; lights off, 7:00 P.M.). Food and water were provided ad libitum. In the morning (between 8:00 and 11:00 A.M.), the animals were given an intraperitoneal injection of 2 g of lipopolysaccharide (LPS) (Sigma-Aldrich; 0111:B4) diluted in 100 l of saline, or as control, saline only. In some experiments, animals were given an intraperitoneal injection of either an unselective Cox inhibitor [indomethacin (Confortid; Alpharma); 10 mg/kg] or a Cox-2 selective inhibitor [parecoxib (Dynastat; Pfizer), 10 mg/kg], 20 min before the LPS injection, or injected with vehicle. Because of the kinetics of parecoxib, the injection was repeated after 3 h, when applicable. The animals were killed by asphyxiation with CO 2 at various time intervals. For plasma protein assays, blood was immediately withdrawn from the right ventricle by heart puncture, collected in EDTA-covered containers (Sarstedt) and centrifuged at 7000 ϫ g (4°C; 7 min) to obtain plasma, which was stored in aliquots at Ϫ70°C. For gene expression analysis with real-time reverse transcription (RT)-PCR, the brain was quickly removed, fresh-frozen on dry ice, and stored at Ϫ70°C. For immunohistochemistry and in situ hybridization, the animals were perfused through the left ventricle with 100 ml of saline, followed by 200 ml of 4% paraformaldehyde in phosphate buffer (0.1 M; pH 7.4; 4°C). The brain was removed, postfixed for 3 h, immersed in 30% sucrose in PBS (0.1 M; pH 7.4) overnight at 4°C, and cut in the transverse plane at 20 m on a freezing microtome. Sections were collected in four series in cold cryoprotectant (0.1 M PBS containing 30% ethylene glycol and 20% glycerol) and stored until use at Ϫ20°C.
Corticosterone, ACTH, , and tumor necrosis factor ␣ protein assays. For detection of corticosterone, plasma was thawed on ice and analyzed using an enzyme immunoassay (IDS OC-TEIA corticosterone kit), according to the manufacturer's instructions. Using a 4-PL curve fit, a standard curve with an R value of 1.000 was obtained. The corticosterone antibody was generated in rabbit with an antigen consisting of corticosterone conjugated to BSA via a CMO [(Ocarboxymethyl) oxime] group introduced synthetically at C3 of the steroid A chain. Assay sensitivity was 0.55 ng/ml. The kit antiserum showed the following cross-reactivity: 6.60% 11-dehydrocorticosterone; 5.93% 11-deoxycorticosterone; 1.39% progesterone; 0.85% cortisol; 0.60% prednisolone; 0.34% 21-deoxycortisol; 0.21% 5␣-pregnan-3,20-dione; and Ͻ0.07% cross-reactivity with the following analytes: tetrahydrocortisone, dexamethasone, dehydroepiandrosterone, prednisone, pregnantriol, 20␤-hydroxypregesterone, 4-pregnen-20␤␣-ol-3-one, estriol, estradiol, estrone, pregnenolone, 17␣-hydroxypregnolone, cortisone, testosterone, 11-desoxycortisol, aldosterone, 17␣-hydroxyprogesterone, and tetrahydrocortisol. The concentrations of ACTH, interleukin-6 (IL-6), and tumor necrosis factor ␣ (TNF␣) in plasma were determined using a bead-based multiplex analysis kit (Millipore; catalog #MBN1A-41K-04; lot 16522), using the Luminex-100 system (Luminex), as described in detail previously (Ruud and Blomqvist, 2007) . Plasma IL-1␤ was measured separately (Millipore; catalog #MCYTO-70K-01; lot 16523), using the same system. For ACTH, a synthetically synthesized hormone was used as immunogen, whereas for cytokines the full recombinant protein, expressed in Escherichia coli, was used. Two separate quality control samples, supplied by the manufacturer and including all analytes, yielded results within the expected concentration range. The minimum detection concentrations for IL-1␤, IL-6, TNF␣, and ACTH were 1.6, 0.6, 1.0, and 1.9 pg/ml, respectively.
Real-time RT-PCR. RNA was extracted using QIAGEN RNeasy Lipid Mini kit (QIAGEN) according to the manufacturer's instructions. The concentrations and purity of the RNA were measured with NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). A sample of 340 ng of RNA from the hypothalamus, dissected as described by Reyes et al. (2003) , was reversely transcribed using SuperScript III First-Strand Synthesis kit with random hexamer primers in a volume of 20 l, according to the manufacturer's protocol (Invitrogen). The efficiency of the RT reaction was evaluated by running five different RT reactions containing different amounts of RNA, which rendered a linear standard curve in real-time PCR using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ␤-actin assays (see below). Real-time RT-PCR analyses were made using instruments, disposables, and chemicals from Applied Biosystems and were performed as singleplex reactions on 10 ng of cDNA in a 96-well format on Fast 7500 Real-Time PCR System, using the TaqMan Fast Universal PCR Master Mix (total reaction volume, 15 l). GAPDH and ␤-actin were chosen as endogenous controls, after we had verified that their expression did not differ between treatment groups or genotypes (data not shown). All gene expression data were verified against both control genes. The following TaqMan Gene Expression Assays were used:
, and Fos (Mm00487425_m1). Gene expression was calculated using the ⌬⌬Ct method (Ct, threshold cycle), where ⌬Ct for each target gene was calculated as ⌬Ct (target) Ϫ ⌬Ct (endogenous control) and ⌬⌬Ct as ⌬Ct (mean, stimulated) Ϫ ⌬Ct (mean, controls) . The relative upregulation or downregulation of gene expression was then calculated as 2 Ϫ(⌬⌬Ct) with SEM obtained by first calculating the SD for the stimulated group (s 1 ) and the control group (s 2 ), and then applying these values in the following formula:
Immunohistochemistry. Every third section throughout the brain was stained for Fos-like immunoreactivity (rabbit anti-Fos 1/1000; Santa Cruz Biotechnology; lot 10503; affinity-purified polyclonal rabbit antiserum raised against a synthetic peptide consisting of amino acids 3-16 at the N-terminal part of Fos of human origin) using the avidin-biotinhorseradish peroxidase complex methodology, as described in detail previously (Ruud and Blomqvist, 2007) . To permit comparison between mice given different treatment (LPS/saline) and being of different genotypes (wild-type/knock-out), sections from all groups were processed simultaneously. A dual-labeling immunohistochemical technique was used for detecting Fos expression in catecholaminergic neurons in the ventrolateral medulla oblongata. In brief, sections were incubated overnight (room temperature) in a mixture of rabbit anti-mouse monoclonal anti-tyrosine hydroxylase antibody (1/8000; ImmunoStar; lot 436017; raised against tyrosine hydroxylase purified from rat PC12 cells) and rabbit anti-Fos antibody. Bound primary antibody was detected by incubation with goat anti-mouse IgG antibody (1:120; Dako) and biotinylated goat anti-rabbit IgG antibody (1/1000; Vector Laboratories), followed first by monoclonal peroxidase anti-peroxidase complex (1:125; Dako) that was visualized with 0.02% 3,3Ј-diaminobenzidine tetrahydrochloride (Sigma-Aldrich) and 0.03% H 2 O 2 to generate a brown cytoplasmic reaction product in tyrosine hydroxylase-expressing neurons, and then by avidin-biotin peroxidase complexes visualized with 3,3Ј-diaminobenzidine tetrahydrochloride and H 2 O 2 as above, but with the addition of 2.25% nickel ammonium sulfate, yielding a black nuclear staining in Fos-expressing cells. Specificity of the anti-Fos antibody was assessed as described in detail previously (Ruud and Blomqvist, 2007) . Specificity of the tyrosine hydroxylase antibody was assessed by comparison of labeling patterns with the consensus distribution of dopamine-␤-hydroxylase immunoreactivity, and by the absence of cross-reactivity against other catecholamine-and indolamine-synthesizing enzymes, according to the manufacturer's Western blot analysis. Analysis of the labeling was done by an observer that was blinded to genotype and treatment of the animal. Nuclear groups were defined under dark-field illumination, using fiber tracts and the contrast between cell groups generated by differences in cell size and packing density as well as fiber content in the neuropil for cytoarchitectonic delineations. Estimates of dual labeling for tyrosine hydroxylase and Fos protein were done on neurons in the ventrolateral medulla oblongata, in a rostrocaudal region limited by the pyramid decussation and the rostral pole of the nucleus ambiguous (i.e., the region that has been shown to project to the PVH) (Sawchenko and Swanson, 1982) .
In situ hybridization. For detection of CRH transcription, a 519-bplong intron fragment of the preproCRH gene (GenBank accession no. NC_000069) was cloned by using PCR with specific primers corresponding to nucleotides 284 -304 (forward primer, 5Ј-ctgtgccttaaaattccgatg-3) and 802-782 (reverse primer, 5Ј-tgggggagaaaggtaagattg-3; Cybergene). Mouse genomic DNA (300 ng; Promega) was used as template. The fragment was amplified for 40 cycles (45 s at 95°C, 45 s at 57°C, and 60 s at 72°C) and subsequently cloned into a pDRIVE vector (QIAGEN). The identity of the cloned fragment was confirmed by sequencing of both strands. A riboprobe was transcribed using Sp6 polymerase (antisense) in the presence of [ 33 P]UTP (PerkinElmer Life and Analytical Sciences) after linearization with BamHI (Promega).
A probe complementary to c-fos mRNA was generated from a c-fos cDNA PBSsk ϩ vector with a 2.1 kb insert corresponding to the entire c-fos coding region (Curran and Morgan, 1985) , which was linearized with SmaI and transcribed with T7 polymerase, also in the presence of [ 33 P]UTP. Unincorporated nucleotides were removed by using Quick Spin columns (Roche) according to the manufacturer's instructions. The in situ hybridization and autoradiography were performed as previously described . Briefly, every fourth section through each brain was mounted on Superfrost Plus slides (Menzel-Gläser), vacuum dried overnight, and postfixed in 4% paraformaldehyde for 30 min. The sections were then incubated at 37°C in proteinase K (10 g/ml) for 30 min, dehydrated in graded concentrations of ethanol, and vacuum dried for ϳ3 h at room temperature. The hybridization solution (0.5 mg/ml tRNA, 0.1 M dithiothreitol, 50% formamide, 10% dextran sulfate, 2% Denhardt's solution, 0.3 M NaCl, 10 mM Tris, and 1 mM ethylenediamine-tetra-acetic acid, pH 8.0) contained a final probe activity of 1 ϫ 10 7 cpm/ml. A total of 150 l of this solution was applied on each slide, which was then coverslipped and sealed with DPX (VWR International). The sections were hybridized at 60°C for 48 h, rinsed in 4ϫ standard saline citrate (SSC) buffer, pH 7.0, and incubated at 37°C with RNase A (20 g/ml) for 30 min, followed by 0.1ϫ SSC at 74°C for 30 min. They were then dehydrated, defatted in xylene, and vacuum dried at room temperature for at least 30 min before being dipped into Kodak NTB-2 nuclear track emulsion (Kodak). After 10 -14 d of exposure, the slides were developed in D-19 developer (Kodak), fixed, and coverslipped.
Quantification of the autoradiographic signal, as seen under dark-field illumination, was performed over the PVH by a blinded observer, using the ImageJ software (version 1.23; W. Rasband, National Institutes of Health, Bethesda, MD). In each animal, the optical density on both sides of PVH was calculated from digital micrographs (taken with a 10ϫ objective, and with a fixed exposure time) of the section that displayed the strongest labeling, as determined qualitatively. Illumination was set so that pixel saturation was avoided and kept constant through the series of measurements. The obtained values were then subtracted from background values in adjacent regions devoid of specific signal.
Statistical analyses. All statistical analyses were performed in SPSS, version 12.01 (SPSS), or Microsoft Excel 2003 (Microsoft). For comparisons between several groups, data were analyzed with ANOVA, followed by post hoc t test, using the Bonferroni correction. For other data, Student's t test was used. A value of p Ͻ 0.05 was considered significant.
Results

Cyclooxygenase inhibition of LPS-induced ACTH and corticosterone release
The effect of unselective Cox inhibition and of Cox-2 selective inhibition on the early ACTH and corticosterone response is shown in Figure 1 , A and B. Treatment of wild-type mice (of the C57/B6 strain) with a selective Cox-2 inhibitor, parecoxib, given intraperitoneally 20 min before LPS in a dose that extinguishes the febrile response in this experimental paradigm (data not shown), only marginally reduced the LPS-induced ACTH and corticosterone response at 1 h, and this effect was not statistically significant. In contrast, treatment with an unselective Cox inhibitor, indomethacin, significantly attenuated the LPS-elicited ACTH release and almost completely extinguished the corticosterone response.
At 6 h after injection, a different picture emerged. Thus, both indomethacin and parecoxib attenuated corticosterone release at this time point (Fig. 2 A) . Notably, the unselective Cox inhibitor indomethacin was not more effective in reducing the corticoste- Figure 1 . Effects of cyclooxygenase inhibition on ACTH (A) and corticosterone (B) release, 1 h after immune challenge. Wild-type mice were injected with indomethacin (indo) (10 mg/kg, i.p.) or parecoxib (parec) (10 mg/kg, i.p.) or, for controls, vehicle, 20 min before an intraperitoneal injection of 2 g of LPS or saline. Because of its kinetics, the injection of parecoxib was repeated after 3 h. n ϭ 7-8 for animals given LPS and n ϭ 5 for those given saline. Error bars indicate SEM. **p Ͻ 0.01 and ***p Ͻ 0.001 between treatments. ns, Not significant. rone response than parecoxib, suggesting that Cox-1 does not contribute to this response. Notably, also, there was a tendency that indomethacin at this time point by itself elevated corticosterone levels. This is consistent with previous reports on a stimulatory effect of this drug on the HPA axis that occurs several hours after drug administration (Weidenfeld et al., 1983) . The data from pharmacological inhibition of the Cox activity were further verified in Cox-2 Ϫ/Ϫ mice (Fig. 2 B) . Although these mice tended to display higher basal plasma corticosterone concentration than wild-type mice, they were close to unresponsive to the LPS stimulus.
LPS-induced ACTH and corticosterone release in mPGES-1
؊/؊ mice The ACTH and corticosterone responses were also examined in mPGES-1 knock-out mice, which previously have been shown to be devoid of induced PGE 2 synthesis on immune challenge . Intraperitoneal injection of LPS (2 g of LPS, i.p.) evoked a strong and similar increase of the ACTH concentration at 1 h after injection in knock-out and wild-type mice (Fig. 3A) . However, at 3 h, the ACTH concentration had decreased in knock-out animals, whereas it remained high in the wild-type mice. At 6 h after injection, no difference was seen between the genotypes, both displaying low concentrations of ACTH.
Both genotypes showed equally strong corticosterone response to LPS at 1 and 3 h. However, at 6 h after injection, at which time point wild-type mice displayed the highest plasma concentration of corticosterone, the knock-out mice showed an attenuated response (Fig. 3B) .
These data hence were consistent with those seen in mice subjected to Cox-2-selective inhibition. They suggest that, although inducible PGE 2 synthesis through Cox-2 and mPGES-1 is involved in the late corticosterone response to immune challenge, it plays little role for the rapid corticosterone release, which seems to be Cox-1 dependent.
To directly examine the contribution of Cox enzymes and mPGES-1, respectively, in the immune-induced corticosterone response at 6 h, we treated mPGES-1 knock-out mice with Cox inhibitors before challenging the mice with LPS. As shown in Figure 3C , parecoxib further reduced the corticosterone response, in addition to the attenuation that resulted from the gene deletion. In contrast, indomethacin treatment had no significant additive effect, a finding that may be explained by its corticosterone-releasing properties (Weidenfeld et al., 1983) . Although the data suggest that mPGES-1 is coupled to Cox-2 in the late immune-induced corticosterone response, they also show that other terminal enzymes, in addition to mPGES-1, may play a role. From a technical perspective, note that the difference in corticosterone release observed at 6 h after injection between LPS-treated mPGES-1 knock-out and wild-type mice obtained from homozygous breeding (Fig. 3B) was corroborated in littermates obtained from animals that had been backcrossed to the parental strain (Fig. 3C, left bars) Plasma levels of IL-1␤, IL-6, and TNF␣ Having established that induced PGE 2 production is involved in the late stress hormone response, we next examined several upstream components involved in this response to identify the underlying mechanisms. First, we measured plasma levels of the proinflammatory cytokines IL-1␤, IL-6, and TNF␣ in LPSchallenged wild-type and mPGES-1 knock-out mice. These cytokines have previously been shown to play a role in the activation of the HPA axis (Turnbull and Rivier, 1999) and to affect central prostaglandin synthesis in inflammatory conditions (Cao et al., 1998; Ek et al., 2001) . The findings are illustrated in Figure 4 . As seen, plasma levels of IL-1␤, IL-6, and TNF␣ were low or below detection limit in naive animals and there were no significant differences between genotypes. Also, the LPS-induced expression of IL-1␤ and IL-6 was similar between wild-type and knock-out mice. For TNF␣, a small difference was seen between genotypes at 6 h after LPS injection ( p Ͻ 0.01), a time point at which the TNF␣ level in both wild-type and mutant mice, however, was low. These data suggest that the effect of induced PGE 2 synthesis on ACTH and corticosterone release is likely to be exerted via a direct, central action. This is consistent with previous findings that intracerebral injection of PGE 2 produces increases in plasma ACTH concentration (Katsuura et al., 1990; Watanabe et al., 1990; McCoy et al., 1994) , and with the demonstration of stimulatory G-protein-coupled PGE 2 receptors (such as EP 4 ) in the PVH, as well in structures known to influence hypophysiotropic neurons, such as the preoptic region and catecholaminergic cells in the ventrolateral medulla (Herman et al., 1996; Zhang and Rivest, 1999; Ek et al., 2000; Oka et al., 2000; Matsuoka et al., 2003) .
CRH gene regulation
We next examined whether wild-type and mPGES-1 Ϫ/Ϫ mice differed in the immune-induced expression of CRH mRNA. Quantitative real-time RT-PCR for CRH mRNA in the hypothalamus demonstrated significantly higher levels in LPS-injected wild-type mice compared with wild-type mice given saline, at 1 h after injection ( p Ͻ 0.05), whereas no significant upregulation was seen in knock-out mice at this time point (Fig. 5A ). There were also significantly higher CRH mRNA levels in the LPStreated wild-type group than in the LPS-treated knock-out group ( p Ͻ 0.05), whereas the CRH mRNA levels in saline-injected mice did not differ between genotypes. At 3 h, both genotypes displayed elevated levels of CRH mRNA after LPS injection compared with saline-injected controls; however, the data on wildtype mice were more consistent as is reflected by a smaller SE and higher statistical significance in that group.
We then used in situ hybridization of CRH heteronuclear (hn) Figure 2 . Effects of cyclooxygenase inhibition on corticosterone response 6 h after immune challenge. A, Wild-type mice were injected with indomethacin (indo) (10 mg/kg, i.p.) or parecoxib (parec) (10 mg/kg, i.p.) or, for controls, vehicle, 20 min before an intraperitoneal injection of 2 g of LPS or saline. Because of its kinetics, the injection of parecoxib was repeated after 3 h. n ϭ 7-8 for animals given LPS and n ϭ 3 for those given saline. B, Wild-type and Cox-2 knock-out mice were injected intraperitoneally with 2 g of LPS or saline. n ϭ 9 -10 for animals given LPS and n ϭ 3-4 for those given saline. Error bars indicate SEM. *p Ͻ 0.05, **p Ͻ 0.01, and ***p Ͻ 0.001 between treatments and genotypes. ns, Not significant.
RNA to examine whether the differences in CRH mRNA expression reflected differences in transcriptional regulation and, if so, where the transcriptional regulation took place. Wild-type and mPGES-1 Ϫ/Ϫ mice were injected with saline or LPS, and transcriptional activity in the hypothalamus was examined after 1 h by autoradiographic detection of a 33 P-labeled riboprobe complementary to a 519-bp-long intronic sequence of the CRH gene. After saline injection, both genotypes displayed only weak CRH hnRNA signal in the PVH (Fig. 5 B, D) . As reported previously (Rivest et al., 1995) , immune challenge with LPS resulted in wildtype mice in upregulation of the CRH hnRNA signal in this nucleus; however, little upregulation was seen in LPS-treated mPGES-1 knock-out mice (Fig. 5C,E) . This difference was verified by quantitative densitometric measurements, which demonstrated a 4.5-fold increased CRH hnRNA expression in the PVH of immune-challenged wild-type mice compared with salinetreated wild-type mice ( p Ͻ 0.01; n ϭ 5 and 3, respectively), whereas no significant difference between treatment groups was seen among mPGES-1 KO mice ( p ϭ 0.26; n ϭ 6 and 3, respectively). No induced CRH hnRNA expression was seen in other parts of the hypothalamus, being consistent with previous observations (Rivest et al., 1995) .
Expression of c-fos mRNA and protein in autonomic relay nuclei
As a final step, we examined neuronal activation, as seen by in situ hybridization for c-fos mRNA and immunohistochemical detection of Fos protein, in the paraventricular hypothalamus (Fig. 6 ) and several brainstem and forebrain autonomic relay nuclei in response to immune challenge with LPS (Figs. 7, 8) . The Fos protein expression in the PVH in Cox-1 knock-out and wild-type mice are shown in Figure 6 A-C, those in Cox-2 knock-out and wild-type mice are illustrated in Figure 6 D-F, and those from mPGES-1 knock-out and wild-type mice are shown in Figure  6G -I. As seen, there was strong induction of Fos protein in LPStreated animals 3 h after injection, regardless of genotype (Fig.   6 B, C, E, F, H, I ). Qualitative examination by a blinded observer suggested a stronger Fos labeling in knock-out mice than in wildtype mice, although this could not be verified statistically by cell counts, because of small sample size (n ϭ 3-4) and considerable interindividual variation. In situ hybridization, performed on sections from mPGES-1 knock-out and wild-type mice killed 1 h after injection, showed strong induction of hybridization signal for c-fos mRNA by LPS in both genotypes (Fig. 6 K, L) , but again with a tendency to more pronounced labeling in the knock-out mice, as determined by qualitative examination. These observations were corroborated by quantitative real-time RT-PCR analysis of c-fos mRNA expression in the hypothalamus of wild-type and mPGES-1 knock-out mice (n ϭ 7-10) at 1 h after intraperitoneal LPS injection. Whereas wild-type mice showed 2.6 times upregulation of c-fos mRNA after intravenous LPS compared with saline ( p Ͻ 0.001), knock-out mice displayed 4.5 times upregulation of the c-fos transcript ( p Ͻ 0.001), from a level that was similar to that of saline-treated wild-type mice. This difference in c-fos mRNA upregulation between genotypes was statistically significant ( p Ͻ 0.01).
To further verify the findings of maintained Fos expression in the knock-out mice, we pretreated wild-type mice with indomethacin or parecoxib, before challenging them with LPS, and measured with real-time RT-PCR the c-fos mRNA level in the hypothalamus at 1 h. We found that neither unselective Coxinhibition with indomethacin, nor selective Cox-2 inhibition Figure 3 . ACTH and corticosterone responses to immune challenge in mPGES-1 knock-out mice. Plasma concentrations of ACTH (A) and corticosterone (B) were examined after intraperitoneal injection of 2 g of LPS (1, 3, and 6 h) or saline (1 h). n ϭ 6 -12 for each data point. C, mPGES-1 knock-out mice were injected with indomethacin (10 mg/kg i.p.) or parecoxib (10 mg/kg i.p.) 20 min before an intraperitoneal injection of 2 g of LPS. The parecoxib injection was repeated after 3 h, and serum corticosterone levels were determined at 6 h after LPS injection. Control wild-type and mPGES-1 knock-outs were given vehicle before injection with LPS. n ϭ 6 -9 for each treatment/genotype. Error bars indicate SEM. *p Ͻ 0.05, **p Ͻ 0.01, and ***p Ͻ 0.001 between treatments and genotypes. , and IL-6 (C) in wild-type (WT) and mPGES-1 KO mice before, and 1, 3, and 6 h after intraperitoneal injection of 2 g of LPS. Except for a small difference in the TNF␣ levels at 6 h (A, inset), there were no statistically significant differences between genotypes. n ϭ 3-5 for the 0 h data points, and 8 -11 for the 1, 3, and 6 h data points. Error bars indicate SEM. **p Ͻ 0.01 between genotypes.
with parecoxib, inhibited the c-fos mRNA expression (Fig. 6 M) . Notably, and in contrast to what was found in mPGES-1 knockout mice, the Cox-inhibited mice did not display significantly higher c-fos mRNA levels than saline-pretreated mice.
Examination of Fos expression in other regions known to be activated in response to immune stimuli, such as the nucleus of the solitary tract and the area postrema, the ventrolateral medulla (VLM), the parabrachial nucleus, the ventromedial preoptic nucleus, and the central nucleus of the amygdala (Elmquist et al., 1993 (Elmquist et al., , 1996 Wan et al., 1993) , also showed LPS-induced induction in both wild-type and gene-deleted mice, with a tendency, as determined qualitatively, that the labeling was stronger in knockout mice than in wild-type mice. Although illustrated for mPGES-1 wild-type and knock-out mice (Fig. 7) , these micrographs are representative also for the findings in the Cox-1 and Cox-2 strains.
Because it is well established that catecholaminergic neurons in VLM are important for the immune-induced activation of the PVH (Weidenfeld et al., 1989; Ericsson et al., 1994; Buller et al., 2001; Schiltz and Sawchenko, 2007) , and because PGE 2 has been suggested to activate these neurons (Ericsson et al., 1997), we specifically examined Fos protein expression in tyrosine hydroxylase-positive neurons in the VLM of wild-type and mPGES-1 knock-out mice, by using a dual-labeling immunohistochemical procedure. The results, shown in Figure  8 , demonstrated that the percentage of tyrosine hydroxylasepositive neurons that also were positive for LPS-induced Fos expression was similar between genotypes.
Discussion
This study demonstrates that constitutive and induced prostaglandin synthesis play distinct roles for early and late phases, respectively, of the immune-elicited stress hormone response. Deletion/inhibition of Cox-2 attenuated the corticosterone release seen at 6 h after intraperitoneal administration of LPS, whereas no effect was observed on this response at 1 h. In contrast, pretreatment of mice with the unselective Cox inhibitor indomethacin that targets Cox-1 in addition to Cox-2 almost completely extinguished the early corticosterone response but was no more effective than selective Cox-2 inhibition in reducing the late corticosterone release. Furthermore, Cox-2 inhibition did not affect ACTH release at 1 h, whereas indomethacin strongly attenuated this early response. We conclude that induced prostaglandin synthesis, via Cox-2, contributes to the delayed HPA axis activation in this experimental paradigm, whereas constitutive prostaglandin synthesis, via Cox-1, is involved in the early response. Although this conclusion is based on deducing the role of Cox-1 from the differential responses to a nonselective Cox-inhibitor and a Cox-2 selective inhibitor, and ideally should be verified in Cox-1-inhibited mice, it is in strong accord with a similar complementary role for Cox-1 and Cox-2 in shaping the febrile response to LPS as well as the associated brain activation pattern (Zhang et al., 2003) .
Although our data from mPGES-1 knock-out mice demonstrate that mPGES-1-derived PGE 2 is involved in the delayed HPA axis response, they also indicated that other prostaglandins may play a role. Hence, when mPGES-1 knock-out mice were treated with a Cox-2 selective inhibitor, LPS-induced corticosterone release was further attenuated. Indeed, it has been demonstrated that, in addition to PGE 2 , PGE 1 and PGF 2␣ elicit ACTH release when injected systemically or into the brain (Katsuura et al., 1990; Nasushita et al., 1997) ; however, although in vitro studies have shown the release of these prostaglandin species from neural cells (Althaus and Siepl, 1997) , their presence in the brain remains to be demonstrated.
Our data show that the effect of immune-induced PGE 2 synthesis on stress hormone release is associated with transcriptional activation of the CRH gene. Whereas immune challenge with LPS in wild-type mice resulted in increased expression of CRH hnRNA in the PVH and elevated levels of CRH mRNA, no corresponding changes were seen in mPGES-1 knock-out mice. Considering that peptide synthesis and release are estimated to occur ϳ60 -90 min after stimulus-activated CRH gene transcription (Watts, 2005) , the differences in CRH mRNA levels between genotypes 1 h after LPS injection will not influence ACTH release at that time point (and which was similar between genotypes), but fit temporally with the differences in plasma ACTH levels seen at 3 h, and with the effect of the gene deletion on corticosterone levels at a later time point. However, additional direct local effects of PGE 2 on CRH or corticosterone release (McCoy et al., 1994; Engström et al., 2008) may also play a role.
A second major finding of the present study is that the Coxdependent activation of the HPA axis seems to be unrelated to or to occur downstream of the LPS-induced neural activation. Thus, Cox-1, Cox-2, or mPGES-1 knock-out mice, or mice treated with Cox inhibitors, did not show any attenuation of the c-fos expression in the PVH and hypothalamus, while displaying extinguished or attenuated stress hormone release. Our data hence indicate that the c-fos expression that occurs in these structures after intraperitoneal injection of LPS results from synaptic input through the vagus nerve via Cox-and mPGES-1-independent mechanisms. A role of vagus nerve signaling in the expression of c-fos after intraperitoneal injection is consistent with the finding that vagotomy or reversible inactivation of the vagus nerve blocked induction of c-fos by LPS given intraperitoneally, whereas it had no effect when the endotoxin was administered intravenously (Wan et al., 1994; Marvel et al., 2004) .
Our observation that c-fos expression in PVH occurs also in the absence of Cox-2 and mPGES-1 is in good accord with the recent observations by Ching et al. (2007) in mice with targeted deletion of the IL-1 receptor type 1 in endothelial cells. These authors showed that c-fos expression in PVH in response to intraperitoneal, but not intravenous, administration of IL-1, was independent on endothelial cell IL-1R1 receptors, whereas induced Cox-2 expression in the brain was extinguished in mutant mice regardless of the route of cytokine administration, indicating the presence of a neuronal pathway for c-fos activation, which is not mediated by central Cox-2-dependent prostaglandin synthesis. Our finding that unselective Coxinhibition with indomethacin, but not selective Cox-2 inhibition, attenuated/ extinguished the early stress hormone response, while not inhibiting c-fos expression, adds to the observations by Ching et al. (2007) by suggesting that that this neuronal pathway neither is Cox-1 dependent. It should be pointed out, however, that the independence of prostaglandin-synthesizing enzymes for the c-fos expression applies to the present experimental paradigm, and that other mechanisms, involving Cox enzymes, may be at play when the immune stimulus is delivered intravenously (Zhang et al., 2003; Ching et al., 2007) , or when LPS is given intraperitoneally at doses that involve spread into the bloodstream (cf. Wan et al., 1994; Sagar et al., 1995; Lacroix and Rivest, 1997) .
There is evidence that cytokines can activate the vagus nerve in both a prostaglandin-dependent and -independent manner; however, the PGE 2 receptors on the vagus nerve are of the EP 3 subtype (Ek et al., 1998) , implying that they play an inhibitory role (Irie et al., 1993) . The dissociation between c-fos expression and HPA axis activation that was seen in the present study after Cox-1 inhibition seems to indicate that Cox-1 is downstream of vagus nerve afferent signaling but upstream of CRH and/or ACTH release. Although the precise site of action of Cox-1 in the HPA axis response remains to be elucidated, it has been reported that cytokines instilled into the hypothalamic median eminence elicit an indomethacin-sensitive ACTH release (McCoy et al., 1994) , implying a direct action of prostaglandins, and hence of prostaglandinsynthesizing enzymes at this site.
Our findings of maintained c-fos expression in mPGES-1 knock-out mice are clearly inconsistent with recent work by Dallaporta et al. (2007) , who reported that Fos protein expression was extinguished in autonomic relay nuclei, including the PVH, in mPGES-1 knock-out mice challenged with LPS. We have no obvious explanation for this discrepancy, with the possible exception that the given dose of LPS (400 g/kg) was approximately fourfold higher and of a different serotype than in the present study, whereas the time point after injection (3 h), as well as the route of administration (intraperitoneal), and the strain and origin of the mice (DBA1/lacJ) (Trebino et al., 2003) were similar. We can only note that our data on intact Fos protein expression in mPGES-1 knock-out mice were corroborated by in situ hybridization for c-fos mRNA in the PVH and of real-time RT-PCR analysis of c-fos mRNA expression in the hypothalamus, as well as by similar findings in Cox-1 and Cox-2 knock-out mice.
On an additional note, our data rather indicate that induced, centrally acting PGE 2 in fact attenuates the immuneinduced Fos expression. We found that c-fos mRNA expression in the hypothalamus, as demonstrated by real-time RT-PCR, was not only maintained, but augmented, in the mPGES-1 knock-out mice, corroborating our qualitative observation that Fos protein expression tended to be stronger in the PVH and other autonomic relay nuclei in mPGES-1 knock-out mice than in wild-type mice. Although these tentative observations will require additional quantitative studies, an attenuated Fos expression by a direct central action of PGE 2 , although contradictory to the fact that PGE 2 injected centrally induces Fos (Lacroix et al., 1996) , would be consistent with the predominant EP 3 receptor expression in many brainstem autonomic relay nuclei (Ek et al., 2000; Engblom et al., 2001) , because the most abundant isoform of the EP 3 receptor is coupled to inhibitory G-proteins that reduce cAMP levels (Irie et al., 1993; Vasilache et al., 2007) . Therefore, as suggested by Zhang et al. (2003) , if anything, PGE 2 binding to the EP 3 receptor may be expected to result in inhibition of these neurons [as is hypothesized for thermosensory preoptic neurons (Lazarus et al., 2007) ] and hence reduced Fos expression, as indicated by the present results. The findings of attenuated Fos expression are also consistent with the negative feedback of PGE 2 on cytokine production in macrophage-like cells (Knudsen et al., 1986; Kunkel et al., 1988) , which includes perivascular macrophages, and although the present data, except for a small late increase in TNF␣, showed no difference in circulating cytokines between mPGES-1 knock-out and wild-type mice, we observed increased transcriptional regulation of IL-6 in the brain of mPGES-1 knock-out mice (Nilsberth et al., 2008) . Although speculative, a negative-feedback mechanism involving PGE 2 , regardless of whether it is mediated directly by EP receptor binding or via attenuated central cytokine production, may help modulating the direct neuronally driven input onto the HPA axis, and would fit with the temporally supplementary roles by which neuronal afferent signaling via the vagus nerve and humoral signaling through induced central prostaglandin synthesis interact in creating the stress hormone response to inflammation, as shown by present experiments. 
